|
CLP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.589999739821E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.71939999804982E-08 |
| Normal-vs-Stage2 |
2.517500E-03 |
| Normal-vs-Stage3 |
1.43720002565573E-09 |
| Normal-vs-Stage4 |
2.50419995850848E-09 |
| Stage1-vs-Stage2 |
2.014000E-01 |
| Stage1-vs-Stage3 |
6.173800E-02 |
| Stage1-vs-Stage4 |
2.295500E-03 |
| Stage2-vs-Stage3 |
1.390340E-02 |
| Stage2-vs-Stage4 |
1.258670E-03 |
| Stage3-vs-Stage4 |
1.231220E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.08269998416932E-09 |
| Normal-vs-AfricanAmerican |
3.13230000004161E-06 |
| Normal-vs-Asian |
2.758100E-03 |
| Caucasian-vs-AfricanAmerican |
2.491600E-01 |
| Caucasian-vs-Asian |
8.044200E-02 |
| AfricanAmerican-vs-Asian |
2.540300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.3281999973519E-08 |
| Normal-vs-Female |
1.93320004449049E-09 |
| Male-vs-Female |
4.512400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.73999994599473E-09 |
| Normal-vs-Age(41-60Yrs) |
4.91939999958113E-07 |
| Normal-vs-Age(61-80Yrs) |
2.46619999977327E-08 |
| Normal-vs-Age(81-100Yrs) |
1.139850E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.580800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.842400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.837800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.022770E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.177800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.023800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.810400E-02 |
| Classical-VS-Follicular |
4.389800E-02 |
| Classical-VS-Other |
5.545000E-01 |
| Classical-VS-Normal |
1.03870000045525E-07 |
| Tall-VS-Follicular |
6.001600E-01 |
| Tall-VS-Other |
9.940600E-01 |
| Tall-VS-Normal |
6.80920000051266E-07 |
| Follicular-VS-Other |
8.619400E-01 |
| Follicular-VS-Normal |
2.32989999515709E-08 |
| Other-VS-Normal |
1.069830E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.51449999985509E-07 |
| Normal-vs-N1 |
1.23870003143622E-09 |
| N0-vs-N1 |
1.017320E-03 |
|
|
